Semaglutide (Ozempic para diabetes, Wegovy para manejo de peso) es un agonista selectivo del receptor GLP-1 que ha demostrado eficacia robusta en ensayos clnicos
GLP-1 agonists produce dramatic weight loss (averaging 15-20% total body weight) primarily through central appetite suppression, eliminating hunger and creating pharmaceutical satiety
Retatrutide is an investigational triple receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from approved agents such as semaglutide or tirzepatide
Disordered Eating Disordered eating is a top concern, with advocates and experts saying that GLP-1s could compound the issue in an already at-risk population
BNT162b2 and mRNA-1273 were the first authorized mRNA vaccines, 19,20 demonstrating the ability of mRNAs to instruct cells to produce viral proteins and induce immune responses
Although DKA is rare with type 2 diabetes and GLP-1 receptor agonists, it remains a medical emergency